CARBIDOPA; LEVODOPA by Novartis is clinical pharmacology mechanism of action parkinson's disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Approved for the treatment of parkinson's disease, post-encephalitic parkinsonism, symptomatic parkinsonism and 1 more indications.
Drug data last refreshed 8h ago
CLINICAL PHARMACOLOGY Mechanism of Action Parkinson's disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Its characteristic features include resting tremor, rigidity, and bradykinetic…
Worked on CARBIDOPA; LEVODOPA at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.